|
US2019099524A1
|
|
Medical devices using coated polymers
|
|
WO2016191793A1
|
|
Methods for screening for fetal trisomies
|
|
WO2015168750A1
|
|
Method of culturing cells
|
|
AU2013228011A1
|
|
The use of a DNA damaging agent and a ligand for the treatment of cancer
|
|
CN104540938A
|
|
Method of treatment
|
|
CN104093358A
|
|
Method and apparatus for detecting the onset of hypoglycaemia
|
|
AU2012313353A1
|
|
Screening method
|
|
WO2011022782A1
|
|
Combinations comprising imatinib mesylate and diclofenac
|
|
WO2009155662A1
|
|
A tumour suppressor protein, caspase-2
|
|
WO2009086591A1
|
|
Diagnostic and therapeutic methods for efmr (epilepsy and mental retardation limited to females)
|
|
WO2009026653A1
|
|
Neuroplasticity assay
|
|
WO2009006688A1
|
|
Regulating il-4 and il- 13 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptor
|
|
WO2008141400A1
|
|
A novel aetiologic agent of acute gastroenteritis (age), diagnostic methods and therapeutic treatment thereof
|
|
US2010310450A1
|
|
method of diagnosis and agents useful for same
|
|
CA2666184A1
|
|
The use of a dna damaging agent and a ligand for the treatment of cancer
|
|
WO2008040098A1
|
|
Immunogenic polypeptides derived from the cleavage loop of precursor hemagglutinin of an influenza virus
|
|
EP2005961A1
|
|
Method of optimizing the treatment of chronic myeloid leukemia with Abl tyrosine kinase inhibitors
|
|
US2010088775A1
|
|
Methods of modulating epithelial-mesenchymal transition and mesenchymal-epithelial transition in cells and agents useful for the same
|
|
CA2612644A1
|
|
Modulation of sphingosine kinase signalling
|
|
WO2006135969A1
|
|
Modulation of sphingosine kinase signalling
|
